Status unknownNCT05854862Updated May 11, 2023

Analysis of Relevant Influencing Factors of Glycemic Control in Patients With Diabetes

An observational study in Glycemic Control, sponsored by Nanjing First Hospital, Nanjing Medical University. Status unknown at 1 site in China. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2023-05-11.

Sponsored by Nanjing First Hospital, Nanjing Medical University · Observational

The sponsor has not verified this record recently (last verified Jan 2023), so the status shown — last known as Recruiting — may be out of date.

Study type: Observational
Model: Cohort
Time perspective: Retrospective
Enrollment: 10,000
Ages: 18 Years to 90 Years
Sex: All

Study summary

This study aims at the analysis of relevant influencing factors of glycemic control in patients with diabetes.

Conditions studied

Glycemic Control

In context

Lead sponsor

Nanjing First Hospital, Nanjing Medical University is the lead sponsor of 213 studies on the registry; 106 are open to participants now.

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: 18 Years to 90 Years
Sexes eligible: All
Accepts healthy volunteers: No
Sampling method: Non-probability sample

Study population

Patients with diabetes who visited in the Department of Endocrinology at the Nanjing First Hospital from August 2013 to the present.

Inclusion criteria

Patients aged 18-90 years with diabetes and the diagnostic criteria of diabetes is according to the World Health Organization in 1999.

Exclusion criteria

Exclusion Criteria:

Patients with stress hyperglycaemia. Patients with severe systemic disease. Patients treated with systemic glucocorticoids within the last three months. Patients without any records about HbA1c, CGM and SMBG.

Study design

Observational model: Cohort
Time perspective: Retrospective
Enrollment: 10,000 participants (estimated)
Patient registry: No

What researchers measure

Primary outcomes

HbA1c
the glycosylated hemoglobin level of patients
Time frame: day 1
TIR
time in range observed using continuous glucose monitoring
Time frame: day 1-14

Secondary outcomes

MBG
mean blood glucose
Time frame: day 1-14
MAGE
Mean amplitude of glycemic excursion assessed by continuous glucose monitoring
Time frame: day 1-14
SD
the standard deviation of mean glucose
Time frame: day 1-14
Incidence of hypoglycemia
Incidence of hypoglycemia
Time frame: day 1-14

Study locations

1 of 1 sites recruiting

Nanjing First hospital
Nanjing, Jiangsu 210006, China
- Jianhua Ma · Contact · majianhua196503@126.com · +862552887091
Recruiting

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

Updates

Tracking since Sep 25, 2026

No changes since tracking began. The registry record was last updated on May 11, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT05854862
Lead sponsor: Nanjing First Hospital, Nanjing Medical University
Responsible party: Sponsor
First posted: May 11, 2023
Start date: Aug 1, 2013
Primary completion: Dec 31, 2023 (estimated)
Completion: Dec 31, 2023 (estimated)
Last update: May 11, 2023

Oversight

Data monitoring committee: Yes
FDA-regulated drug: No
FDA-regulated device: No

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Nanjing First Hospital, Nanjing Medical University

Start the discussion